Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immutep Limited filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose ADRs trade on Nasdaq and whose ordinary shares trade on ASX. Recent Form 6-K reports furnish ASX releases, quarterly activities reports and half-year financial information covering research and development spending, cash resources, clinical trial expenses and operating results.
The filings also record program-specific disclosures for eftilagimod alfa and IMP761, including TACTI-004, INSIGHT-003 and EFTISARC-NEO updates, FDA orphan drug designation in soft tissue sarcoma, development collaborations, and Nasdaq minimum-bid-price compliance notices. These documents describe clinical, regulatory, liquidity and capital-market matters for Immutep's LAG-3 immunotherapy portfolio.